Our study highlights that a substantial differences exist in COVID-19-related and classical ARDS, as the biomarkers levels of endothelial injury, such as Ang-2 and ICAM-1, were higher in COVID-19-related ARDS, supporting a different pathophysiological pathway of these two syndromes, as recently suggested [11, 17]. The gene discussed is ICAM1; the disease is COVID-19.